Onyx CEO challenges Amgen-only talk in buyout process

Onyx Pharmaceuticals ($ONXX) CEO Tony Coles has held his cards about his company's sales process close to the vest. In keeping with this practice, the chief executive kept his comments about the process vague and brief during a second-quarter earnings call Thursday following reports that Amgen ($AMGN) alone was readying a $130-per-share deal to acquire his company. "The process is ongoing with multiple parties currently engaged in discussions," Coles said, as quoted by Bloomberg. The comment doesn't necessarily say that multiple bidders are still interested in Onyx, but one could interpret it that way. In which case Amgen might face some competition in its pursuit of South San Francisco-based Onyx. More

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.